Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBIT (2016 - 2025)

Voyager Therapeutics' EBIT history spans 11 years, with the latest figure at -$29.9 million for Q4 2025.

  • On a quarterly basis, EBIT rose 21.85% to -$29.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$131.8 million, a 58.3% decrease, with the full-year FY2025 number at -$131.8 million, down 58.3% from a year prior.
  • EBIT hit -$29.9 million in Q4 2025 for Voyager Therapeutics, up from -$30.6 million in the prior quarter.
  • Over the last five years, EBIT for VYGR hit a ceiling of $122.9 million in Q1 2023 and a floor of -$39.9 million in Q4 2023.
  • Historically, EBIT has averaged -$15.6 million across 5 years, with a median of -$25.3 million in 2021.
  • Biggest five-year swings in EBIT: plummeted 530.78% in 2022 and later surged 675.57% in 2023.
  • Tracing VYGR's EBIT over 5 years: stood at $5.7 million in 2021, then plummeted by 530.78% to -$24.6 million in 2022, then crashed by 62.3% to -$39.9 million in 2023, then rose by 3.93% to -$38.3 million in 2024, then grew by 21.85% to -$29.9 million in 2025.
  • Business Quant data shows EBIT for VYGR at -$29.9 million in Q4 2025, -$30.6 million in Q3 2025, and -$36.6 million in Q2 2025.